<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073576</url>
  </required_header>
  <id_info>
    <org_study_id>CH-1803-AHCL</org_study_id>
    <nct_id>NCT04073576</nct_id>
  </id_info>
  <brief_title>Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.</brief_title>
  <official_title>Randomized Cross Over Trial of the MiniMed™ 670G 4.0 Insulin Pump, Comparing Advanced Hybrid Closed Loop Mode With Sensor Augmented Pump Therapy in Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christchurch Clinical Studies Trust Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Christchurch Clinical Studies Trust Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced&#xD;
      Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin delivery systems are an increasingly popular treatment option for Type I Diabetes&#xD;
      (T1D). Delivery systems consist of an insulin pump, a glucose sensor with a transmitter&#xD;
      attached, and a maths program (algorithm) built into the pump. The algorithm uses sensor&#xD;
      glucose levels to decide how much insulin should be delivered by the pump.&#xD;
&#xD;
      This study aims to see how well a new algorithm controls blood glucose levels in T1D. The&#xD;
      study uses the MiniMed 670G 4.0 insulin pump and compares two different algorithms:&#xD;
&#xD;
        1. Advanced Hybrid Closed Loop (AHCL - the new algorithm)&#xD;
&#xD;
        2. Sensor augmented pump therapy with predictive low-glucose management (SAP with PLGM).&#xD;
&#xD;
      Approximately 60 participants with T1D, aged 7 - 80 years, will take part in the study.&#xD;
&#xD;
      Every participant will receive the following two treatment algorithms in random order, with a&#xD;
      two-week washout between treatments:&#xD;
&#xD;
        -  MiniMed 670G 4.0 insulin pump in AHCL mode for 4 weeks.&#xD;
&#xD;
        -  MiniMed 670G 4.0 insulin pump in SAP + PLGM mode for 4 weeks.&#xD;
&#xD;
      During the study insulin pump data will be uploaded and changes in health will be monitored.&#xD;
      In addition, participants will complete 3-day food diaries and a number of questionnaires.&#xD;
      Participants at the Dunedin site will also be asked to complete home sleep studies during the&#xD;
      trial (optional).&#xD;
&#xD;
      The results of the study will be used to further develop insulin delivery systems. It is&#xD;
      hoped this may improve treatment for people with diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">October 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of the AHCL system</measure>
    <time_frame>4 weeks</time_frame>
    <description>percentage of sensor glucose values between 3.9 - 10.0 mmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the AHCL system</measure>
    <time_frame>4 weeks</time_frame>
    <description>percentage of sensor glucose values &lt;3.9 mmol/L and &gt; 10 mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>AHCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced Hybrid Closed Loop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAP+PLGM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sensor Augmented Pump with Predictive Low Glucose Monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AHCL</intervention_name>
    <description>Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.</description>
    <arm_group_label>AHCL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAP+PLGM</intervention_name>
    <description>Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.</description>
    <arm_group_label>SAP+PLGM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 7 - 80 years inclusive.&#xD;
&#xD;
          2. Type I diabetes as per the American Diabetes Association Classification, diagnosed at&#xD;
             least 1 year prior to Study Day 1.&#xD;
&#xD;
          3. On insulin pump therapy for at least 6 months prior to study Day 1.&#xD;
&#xD;
          4. Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8&#xD;
             units.&#xD;
&#xD;
          5. Willing and able to adhere to the study protocol.&#xD;
&#xD;
          6. Access to the internet and a computer system that meets requirements for uploading the&#xD;
             study pump.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mean HbA1c more than 10.0% (86 mmol/mol) within 6 months prior to Study Day 1 (minimum&#xD;
             of one test).&#xD;
&#xD;
          2. Use of a medication indicative of diabetes complications (ACE inhibitors and statins&#xD;
             are permitted).&#xD;
&#xD;
          3. Use of systemic glucocorticoids within 2 weeks prior to the Baseline visit.&#xD;
&#xD;
          4. Current use of SGLT-2 or GLP-1 medications.&#xD;
&#xD;
          5. History or current evidence of significant seizure disorder, renal impairment or&#xD;
             cardiovascular disease (including uncontrolled hypertension), in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          6. History of severe visual impairment, in the opinion of the Investigator.&#xD;
&#xD;
          7. If female, is pregnant or plans to become pregnant while participating in the study. A&#xD;
             positive urine pregnancy test at Screening is exclusionary.&#xD;
&#xD;
          8. Any clinically significant concomitant disease or condition that could interfere with,&#xD;
             or for which the treatment of might interfere with, the conduct of the study, or that&#xD;
             would, in the opinion of the investigator, pose an unacceptable risk to the subject in&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Sanders</last_name>
      <phone>+6433729477</phone>
      <email>jo@ccst.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

